Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients - PubMed (original) (raw)
Comparative Study
. 2008 Dec;10(12):1204-11.
doi: 10.1111/j.1463-1326.2008.00880.x. Epub 2008 May 12.
Affiliations
- PMID: 18476983
- DOI: 10.1111/j.1463-1326.2008.00880.x
Comparative Study
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
Y Miyazaki et al. Diabetes Obes Metab. 2008 Dec.
Abstract
Objective: We examined the effects of rosiglitazone treatment on profiles of adipocytokines levels, postprandial insulin and glucose excursion, lipids levels, comparing with those of pioglitazone treatment in patients with type 2 diabetes mellitus (T2DM).
Methods: Changes in body weight, haemoglobin A(1c )(HbA(1c)), glucose/insulin/C-peptide/free fatty acid (FFA) during 75 g oral glucose tolerance test (OGTT), HDL-/LDL-cholesterol, triglyceride (TG) and adipocytokines [tumour necrosis factor (TNF)-alpha, leptin and adiponectin] were measured in T2DM patients treated with rosiglitazone, 8 mg/day (n = 35), or pioglitazone, 45 mg/day (n = 21), for 3 months.
Results: After rosiglitazone or pioglitazone treatment, HbA(1c )(8.6-7.2 vs. 8.3-6.9%, rosiglitazone vs. pioglitazone), fasting plasma glucose (190-144 vs. 178-140 mg/dl), fasting FFA (729-595 vs. 641-526 microEq/l), mean plasma glucose-OGTT (292-229 vs. 285-233 mg/dl) and mean FFA-OGTT (580-430 vs. 488-377 microEq/l) decreased similarly and all were statistically significant (p < 0.01). The insulinogenic index (DeltaI(0-120)/DeltaG(0-120)) (0.19-0.30 vs. 0.17-0.26) and Matsuda index of insulin sensitivity (2.0-3.1 and 2.7-4.3) increased (p < 0.01) similarly, despite increase in body weight (85-88 vs. 81-84 kg). TNF-alpha (3.8-3.4 vs. 5.2-4.5 pg/ml) decreased (p < 0.05) and adiponectin (6.3-17.8 vs. 7.1-16.4 microg/ml) increased (p < 0.01), while leptin did not change following either treatment. After rosiglitazone treatment, plasma HDL-cholesterol (34-38 mg/dl) and LDL-cholesterol (103-120 mg/dl) increased (p < 0.01), while TGs (177-167 mg/dl) did not change significantly. After pioglitazone treatment, plasma HDL-cholesterol (34-37 mg/dl) increased (p < 0.05), while LDL-cholesterol (104-105 mg/dl) did not change and TGs (153-106 mg/dl) decreased (p < 0.01).
Conclusions: Rosiglitazone and pioglitazone have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels. However, pioglitazone has a more beneficial effect on the plasma lipid profile than rosiglitazone.
Similar articles
- Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M; GLAC Study Group. Tan MH, et al. Diabet Med. 2004 Aug;21(8):859-66. doi: 10.1111/j.1464-5491.2004.01258.x. Diabet Med. 2004. PMID: 15270789 Clinical Trial. - Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Sharma PK, et al. Clin Endocrinol (Oxf). 2006 Dec;65(6):722-8. doi: 10.1111/j.1365-2265.2006.02658.x. Clin Endocrinol (Oxf). 2006. PMID: 17121522 Clinical Trial. - Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF. Derosa G, et al. Metabolism. 2008 Nov;57(11):1552-7. doi: 10.1016/j.metabol.2008.06.010. Metabolism. 2008. PMID: 18940393 Clinical Trial. - Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ. Betteridge DJ. Diabetes Obes Metab. 2007 Sep;9(5):640-7. doi: 10.1111/j.1463-1326.2007.00715.x. Diabetes Obes Metab. 2007. PMID: 17697057 Review. - [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W. Haberbosch W. Herz. 2007 Feb;32(1):51-7. doi: 10.1007/s00059-007-2843-5. Herz. 2007. PMID: 17323035 Review. German.
Cited by
- Leptin signaling in breast cancer and its crosstalk with peroxisome proliferator-activated receptors α and γ.
Dana N, Ferns GA, Nedaeinia R, Haghjooy Javanmard S. Dana N, et al. Clin Transl Oncol. 2023 Mar;25(3):601-610. doi: 10.1007/s12094-022-02988-4. Epub 2022 Nov 8. Clin Transl Oncol. 2023. PMID: 36348225 Review. - Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes.
Moody AJ, Molina-Wilkins M, Clarke GD, Merovci A, Solis-Herrera C, Cersosimo E, Chilton RJ, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA. Moody AJ, et al. Diabetes Obes Metab. 2023 Feb;25(2):426-434. doi: 10.1111/dom.14885. Epub 2022 Nov 4. Diabetes Obes Metab. 2023. PMID: 36204991 Free PMC article. - Molecular Pharmacology of Inflammation Resolution in Atherosclerosis.
Kotlyarov S, Kotlyarova A. Kotlyarov S, et al. Int J Mol Sci. 2022 Apr 27;23(9):4808. doi: 10.3390/ijms23094808. Int J Mol Sci. 2022. PMID: 35563200 Free PMC article. Review. - The forgotten type 2 diabetes mellitus medicine: rosiglitazone.
Xu B, Xing A, Li S. Xu B, et al. Diabetol Int. 2021 Jun 29;13(1):49-65. doi: 10.1007/s13340-021-00519-0. eCollection 2022 Jan. Diabetol Int. 2021. PMID: 35059243 Free PMC article. Review. - Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R, Behdarvand T, Afarin R, Yaghooti H, Jalali MT, Mohammadtaghvaei N. Akbari R, et al. BMC Pharmacol Toxicol. 2021 Oct 1;22(1):53. doi: 10.1186/s40360-021-00524-8. BMC Pharmacol Toxicol. 2021. PMID: 34593018 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous